CHAPTER 47 MYASTHENIA GRAVIS & ALZHEIMER
DISEASE EXAMS WITH 100% ACCURATE ANSWERS
UPDATED 2025/2026 BEST SOLUTION RATED A+ FOR
SUCCESS
Donepezil (Aricept): Classification and Action
Reversible cholinesterase inhibitor; increases acetylcholine by inhibiting
its metabolism to slow neuronal degradation.
Donepezil (Aricept): Indication
Delays progression of Alzheimer's disease for approximately 55 weeks.
Donepezil (Aricept): Adverse Effects
Headache, dizziness, vertigo, insomnia, nausea, vomiting, diarrhea, GI
bleeding, and heart conduction disorders.
Donepezil (Aricept): Contraindications
Known lung disease or heart disease (e.g., sick sinus syndrome).
Donepezil (Aricept): Administration
Once daily at bedtime.
Donepezil (Aricept): Monitoring
Monitor liver function; report jaundice, severe GI symptoms, or
neurologic changes.
Memantine (Namenda): Classification and Action
NMDA receptor antagonist; reduces glutamate-mediated neurotoxicity
and preserves synaptic function.
Memantine (Namenda): Indication
DISEASE EXAMS WITH 100% ACCURATE ANSWERS
UPDATED 2025/2026 BEST SOLUTION RATED A+ FOR
SUCCESS
Donepezil (Aricept): Classification and Action
Reversible cholinesterase inhibitor; increases acetylcholine by inhibiting
its metabolism to slow neuronal degradation.
Donepezil (Aricept): Indication
Delays progression of Alzheimer's disease for approximately 55 weeks.
Donepezil (Aricept): Adverse Effects
Headache, dizziness, vertigo, insomnia, nausea, vomiting, diarrhea, GI
bleeding, and heart conduction disorders.
Donepezil (Aricept): Contraindications
Known lung disease or heart disease (e.g., sick sinus syndrome).
Donepezil (Aricept): Administration
Once daily at bedtime.
Donepezil (Aricept): Monitoring
Monitor liver function; report jaundice, severe GI symptoms, or
neurologic changes.
Memantine (Namenda): Classification and Action
NMDA receptor antagonist; reduces glutamate-mediated neurotoxicity
and preserves synaptic function.
Memantine (Namenda): Indication
